AQEMIA
AQEMIA, a leading company in generative-AI-driven drug discovery, announces the achievement of a research milestone in its collaboration with Servier, an international independent pharmaceutical company, to address an undruggable target in immuno-oncology.
Based on AQEMIA ‘s quantum and statistical physics-based calculations, and within the span of a few months, a series of molecules experimentally active on an undruggable target in immuno-oncology have been successfully identified. This milestone triggers an undisclosed payment to AQEMIA.
"Our teams are very proud of this achievement that demonstrates the power of AQEMIA's cutting-edge generative AI and deep physics in creating novel, patentable molecules to meet therapeutic needs that are still immense, particularly in the field of immuno-oncology. Within the framework of our collaboration with Servier, we have reached the stage where a series of molecules are subsequently proven impactful in vitro and in vivo assays. " said Maximilien Levesque, PhD, CEO and Co-founder of AQEMIA.
This critical milestone is a continuation of Servier and AQEMIA’s successful partnership program, initiated in December 2021, to accelerate drug candidate discovery in immuno-oncology using artificial intelligence and deep physics.
AQEMIA has worked on more than a dozen in-house therapeutic programs in oncology and immuno-oncology, as well as in new therapeutic areas such as immunology, inflammation and diseases of the central nervous system. To date, AQEMIA’s three most advanced programs are being tested against cancers in animals.
About AQEMIA
AQEMIA is a next-gen techbio generating one of the world's fastest-growing drug discovery pipeline. Our mission is to design fast many innovative drug candidates for critical diseases. Our differentiation lies in our unique quantum and statistical mechanics algorithms to power a generative artificial intelligence designing novel drug candidates, without the need to train on experimental data. We already delivered several drug discovery successes in internal pipeline as well as in collaboration with Pharma companies - most advanced programs being currently in vivo optimization.
For more information, visit AQEMIA.com and our LinkedIn
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240627468833/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Convatec Selects LTIMindtree for Strategic, AI-Powered SAP S/4HANA Transformation17.11.2025 09:30:00 CET | Press release
LTIMindtree [NSE: LTIM, BSE: 540005], a global technology consulting and digital solutions company, has announced its selection as a strategic partner by Convatec, a leading global medical products and technologies company, for the implementation of SAP’s Digital Core – S/4HANA. As part of this engagement, LTIMindtree will support Convatec to implement SAP’s Digital Core – S/4HANA across its Convatec’s business operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251114580133/en/ Srini Rao, EVP and Chief Business Officer - Europe at LTIMindtree & Angie Goodwin, Chief Digital Information Officer at Convatec LTIMindtree will refresh Convatec’s SAP S/4HANA landscape, streamline business processes, and enable intelligent, AI-powered digital operations. The deployment will support Convatec’s goals for process standardisation and operational efficiency, forming the foundation for its next phase of strategic technology transf
GoWit Secures Strategic Investment Led by Nuwa Capital to Drive the Next Era of AI Retail Media in EMEA17.11.2025 09:09:00 CET | Press release
GoWit, the leading AdTech company in connected commerce and retail media, announced a strategic investment round led by Nuwa Capital, with participation from existing investors Formus Capital, APY Ventures, and DCP. The investment marks a milestone in GoWit’s mission to expand AI-powered commerce and retail media network and strengthen its leadership across EMEA. Accelerating AI-Powered Retail Media Across EMEA The new capital will fuel GoWit’s expansion and the development of next-generation AI tools to enhance ad performance, data intelligence, and monetization for retailers, brands, and agencies. GoWit’s technology is trusted by leading retailers and marketplaces, including Carrefour (Turkey), Union Coop (UAE), Raneen (Egypt), Toters Delivery (Lebanon), Mumzworld (UAE), and Heureka Group (Czech Republic). The company collaborates with ecosystem partners such as Goldbach (Switzerland), Spike Media (MENA), and Akinon (EMEA), building a connected retail media infrastructure. “We built
TRU Simulation’s Bell 525 Flight Simulator Receives FAA Interim Level C Qualification17.11.2025 09:00:00 CET | Press release
TRU Simulation + Training Inc., a Textron Inc. (NYSE:TXT) company, and an affiliate of Textron Aviation Inc. and Bell Textron Inc. today announced its Bell 525 Full Flight Simulator (FFS) located at the Bell Training Academy received Interim Level C qualification from the Federal Aviation Administration (FAA). Bell Textron Inc. has designed and will manufacture the Bell 525 helicopter. By achieving this milestone, pilots can earn more flight hours on the Bell 525 platform ahead of the rotorcraft’s expected FAA type certification. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117520706/en/ TRU Simulation’s Bell 525 Flight Simulator receives FAA Interim Level C qualification “The accuracy and realism of our Flight Simulation Devices play a crucial role in ensuring that pilots can effectively translate their training into real-world scenarios,” said Jerry Messaris, vice president and general manager, TRU Simulation. “This q
Polpharma Biologics Confirms U.S. Launch of Tyruko® (natalizumab), the First and Only Biosimilar for Multiple Sclerosis17.11.2025 08:52:00 CET | Press release
Polpharma Biologics, a biopharmaceutical company group focused on biosimilars development and manufacturing, today confirmed that Sandoz Tyruko® (natalizumab-sztn) is now available to patients in the United States. Tyruko® is the first and only FDA-approved biosimilar of natalizumab for the treatment of relapsing forms of multiple sclerosis (MS), and also for adult patients with moderately to severely active Crohn’s disease1. Tyruko® was developed by Polpharma Biologics and will be commercialized in the U.S. by its collaboration partner Sandoz, under an exclusive global license agreement. The launch marks a significant milestone in expanding access to high-quality, affordable treatment options for patients living with MS and Crohn’s disease in the United States. Emmanuelle Lepine, Chair of the Supervisory Board, Polpharma Biologics, commented: "The U.S. launch of Tyruko® marks a pivotal moment not only for Polpharma Biologics, but for patients across the United States. This milestone r
Lone Star Acquires Multi-Asset Real Estate Portfolio from St. James’s Place17.11.2025 08:01:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Real Estate Fund VII, L.P. has successfully completed the acquisition of a multi-asset real estate portfolio from St. James’s Place (SJP) and its Property Unit Trust and Life and Pensions Trust. SJP was advised by Invesco Real Estate, the global real estate investment manager, on the sale of the portfolio. The portfolio comprises 16 high-quality assets across the UK, including multi-let industrial (“MLI”), retail, and office properties. The largest component is the MLI portfolio, which consists of 10 separate property assets predominantly located in Greater London and South East England, and offering access to major transportation and industrial hubs — making them highly attractive for last-mile delivery and regional distribution. The office properties are all situated in London, while the retail assets consist of high-quality retail warehouses with strong tenant bases. Lone Star will implement an active asset
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom